Alcohol use disorder is a condition that can deeply affect a person’s life. It often leads to health problems, emotional distress, and social difficulties.
Around the world, it is responsible for millions of deaths each year. Although therapy and medications exist, many people still struggle to reduce their drinking, which is why researchers continue to search for better treatments.
A recent study has explored a new and surprising option. Scientists tested a drug called semaglutide, which is already used to treat diabetes and support weight loss. This drug works by changing how the body feels hunger and fullness.
Because it can affect brain signals related to reward and cravings, researchers wanted to see if it could also reduce the desire to drink alcohol.
The study involved 108 adults in Denmark who were living with obesity and alcohol use disorder. All participants wanted help with their drinking.
They were given cognitive behavioral therapy, which helps people change harmful habits by understanding their thoughts and actions. In addition, each person received either a weekly injection of semaglutide or a placebo.
At the start of the study, participants reported heavy drinking on about 17 days in the previous month. Over the next six months, their drinking levels were tracked carefully. The results showed that both groups improved, but the group taking semaglutide improved more.
By the end of the study, people in the semaglutide group had reduced their heavy drinking days to about five days per month. Those in the placebo group reduced their heavy drinking to about nine days per month. This shows that semaglutide led to a greater reduction in heavy drinking.
The total amount of alcohol consumed also dropped significantly. Participants taking semaglutide reduced their intake from about 2,200 grams to around 650 grams per month. The placebo group also improved, but their intake only dropped to about 1,175 grams. This suggests that semaglutide had a stronger effect on reducing alcohol use.
The research was published in The Lancet, which is one of the leading medical journals in the world. This adds weight to the findings. However, the authors also noted some important limitations.
The number of participants was small, and the study did not track what happened after the treatment ended. This means we do not know if the benefits continued over time.
Looking at the study more closely, it offers an exciting new idea. It suggests that drugs designed for one purpose, such as weight loss, may also help with other conditions like alcohol use disorder. This could be especially helpful for people who have both obesity and alcohol-related problems.
At the same time, caution is needed. One study is not enough to change treatment guidelines. More research with larger groups of people is needed to confirm the results. It is also important to study long-term safety and effectiveness.
Overall, this study adds to growing evidence that GLP-1 drugs may have wider benefits than previously thought. If future research supports these findings, semaglutide could become part of a new approach to treating alcohol use disorder. This could help many people reduce their drinking and improve their health.
If you care about wellness, please read studies about how alcohol affects liver health and disease progression, and even one drink a day could still harm blood pressure health.
For more health information, please see studies that your age may decide whether alcohol is good or bad for you, and people over 40 need to prevent dangerous alcohol/drug interactions.
Source: The Lancet.
